• Corpus ID: 32276862

Tumor markers CA 19-9 , CA 242 and CEA in the diagnosis of pancreatic cancer : a meta-analysis

  title={Tumor markers CA 19-9 , CA 242 and CEA in the diagnosis of pancreatic cancer : a meta-analysis},
  author={Yimin Zhang and Jun Yang and Hongjuan Li and Yihua Wu and Honghe Zhang and Wenhu Chen},
Background: Pancreatic cancer has the worst prognosis and early detection is crucial for improving patient prognosis. Therefore, we performed a meta-analysis to evaluate and compare the sensitivity and specificity of single test of CA19-9, CA242, and CEA, as well as combination test in pancreatic cancer detection. Methods: We searched PubMed, Embase, Medline, and Wanfang databases for studies that evaluated the diagnostic validity of CA19-9, CA242, and CEA between January 1990 and September… 

Figures and Tables from this paper

Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy
This study aims to evaluate and compare the accuracy of five common tumour biomarkers (CA242,carcino-embryonic antigen (CEA), CA125, microRNAs and K-ras gene mutation and CA19-9 and their combinations for diagnosing pancreatic cancer using network meta-analysis method, and to rank these tests using a superiority index.
Serum tumor markers used for predicting esophagogastric junction adenocarcinoma in esophageal malignancy
Synchronous exertion of CA72-4, CEA, SCC, and CA19-9 could be a valuable method to distinguish esophagogastric junction adenocarcinoma from esophageal squamous cell carcinoma.
CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma
The data suggest that CEA might help to identify CCA patients with an unfavourable prognosis after tumor resection, and only CEA but not CA19-9 represented an independent predictor of survival in multivariate Cox-regression analysis.
Assessing the merits of existing pancreatic cancer biomarkers
Other potential PDAC marker candidates are Laminin g2A, Cyclophilin B and blood circulating adipokines, which seem to hold particular promise, which might in the future be introduced into clinical practice however further studies are still required.
Treatment optimization of locally advanced and metastatic pancreatic cancer (Review)
A comprehensive review of PDAC epidemiology, physiology and treatment is provided and guidelines on patient treatment are suggested.
Circulating microRNAs as promising diagnostic biomarkers for pancreatic cancer: a systematic review
In conclusion, circulating miRNAs may hold potential to be used as noninvasive diagnostic biomarkers for PC, but large-scale studies are still needed to validate the promising mi RNAs and optimize the miRNA panels.
Increased expression of tumor necrosis factor receptor-associated factor 6 in pancreatic cancer and its clinical significance
Tumor necrosis factor receptor-associated factor 6 is up-regulated in pancreatic ADC tissues and could serve as a tumor promoter in the initiation and progression of pancreatIC ADC.
A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma
  • I. YuW. Cheung
  • Medicine
    Canadian journal of gastroenterology & hepatology
  • 2018
A comprehensive overview of the contemporary treatment options for pancreatic cancer is provided and some insights into the existing landscape and future directions of biomarker development for this disease are offered.
Relationship between expression of MAS-related GPR family member D and clinicopathological characteristics in pancreatic cancer
High expression of MRGPRD might play vital roles in the neural invasion and lymph node metastasis of PC, however, this finding needs to be confirmed with larger size of patients.
Advances in pancreatic cancer biomarkers
Current and future biomarkers that has potential serve as critical tools for early diagnostic, predictive and prognostic indications in pancreatic cancer are reviewed.


CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis
The meta-analysis showed that CA242 and CA19-9 could play different roles in the diagnosis of pancreatic cancer, although the sensitivity of CA242 is lower than that of CA 19-9, and its specificity is greater.
The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
  • X. NiX. Bai P. Zhao
  • Medicine, Biology
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2005
Values of CA19-9,CA242,CEA,and CA125 in Diagnosis and Prognosis for Pancreatic Cancer
CA19-9 or CA242 is a valuable marker for evaluating treatment effects and estimating prognosis and combined detection of tumor markers CA19- 9+CA242+CEA can improve the diagnostic specificity.
Value of combined detection of CEA,CA199 and CA242 in diagnosis of pancreatic carcinoma
Combined detection of CEA,CA199 and CA242 had ideal value in clinic diagnosis of pancreatic carcinoma and the specificity and positive predictive value in the combined detection were elevated.
Significance of Serum CA19-9 Detection in the diagnosis of pancreatic cancer
Combined assay of tumor markers is helpful in the early diagnosis of pancreatic cancer and among these tumor markers CA19-9 was the best diagnostic index.
Diagnosis of Pancreatic Cancer through Detecting 4 Tumor Markers in Serum
(TSGF+CA 242) group is superior to other combinations in sensitivity, specificity, effectiveness and positive estimated value and is more economical for the patients.
Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Evaluating the clinical significance of combined measurement of multiple serum tumor markers and the application of the receiver-operating characteristic (ROC) curves in the differential diagnosis of solid lesions located at the pancreatic head found CA19-9 has the best diagnostic ability.
Role of Combined Detection of Serum Tumor Markers in Diagnosis of Pancreatic Cancer
The combined detection of serum CA199,CA242 and CEA could improve the sensitivity and specificity in diagonosis and differential diagnosis of pancreatic cancer.
Assay and clinical significance of serum tumor markers in diagnosis of pancreatic carcinoma
Serum CA199, CA125 and CA242 are the preferred tumor markers to be used in the diagnosis and prognosis of pancreatic carcinoma.
Advances in pancreatic cancer research: moving towards early detection.
Advances in the identification of novel circulating biomarkers including serological signatures, autoantibodies, epigenetic markers, circulating tumor cells and microRNAs suggest they can be used as potential tools for the screening of precursors and early stage PDAC in the future, but proper screening strategies based on effective screening methodologies need to be tested for clinical application.